| Bioactivity | ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF165 binding to NRP-1, used in the research of angiogenesis[1]. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes[2]. | ||||||
| Target | Neuropilin-1 | ||||||
| Invitro | ATWLPPR Peptide TFA is a selective neuropilin-1 inhibitor, inhibits VEGF165 binding to NRP-1 by 82% at 100 μM[1]. | ||||||
| In Vivo | ATWLPPR (400 μg/kg, s.c.) preserves vascular integrity and decreases the oxidative stress level, possibly reduces the early retinal damage caused by diabetes[2].ATWLPPR prevents the increase of inflammation-associated proteins (GFAP, VEGF and ICAM-1) in the retina[2]. | ||||||
| Name | ATWLPPR Peptide TFA | ||||||
| Formula | C42H62F3N11O11 | ||||||
| Molar Mass | 954.00 | ||||||
| Appearance | Solid | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture and light
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
||||||
| Reference | [1]. Starzec A, et al. Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex. Peptides. 2007 Dec;28(12):2397-402. [2]. Wang J, et al. The Neuropilin-1 Inhibitor, ATWLPPR Peptide, Prevents Experimental Diabetes-Induced Retinal Injury by Preserving Vascular Integrity and Decreasing Oxidative Stress. PLoS One. 2015 Nov 10;10(11):e0142571. |
ATWLPPR Peptide TFA
CAS: F: C42H62F3N11O11 W: 954.00
ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF165 binding to NRP-1, used
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.